HMGB2 Deficiency in Bone Marrow Mesenchymal Stem Cells Promotes Age‐Related Osteoporosis by Inhibiting Osteoblast Differentiation via Inflammatory Factors
The FASEB Journal · 2025
DOI: 10.1096/fj.202500484rrrr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Zhiliang Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Osteoporosis, HMGB2 Protein, Cell Differentiation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: | Natural Science Foundation of Shandong Province (), Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
With the global rise in osteoporosis due to aging, impaired osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) has emerged as a critical pathogenic factor. Although high mobility group box 2 (HMGB2) is implicated in BMSC aging and organismal senescence, its mechanistic role in osteoporosis remains unclear. Here, we investigate HMGB2's regulatory effects on BMSC osteogenic differentiation under aging conditions. Using an H 2 O 2 ‐induced BMSC senescence model, we demonstrate that cellular senescence suppresses osteogenic differentiation, evidenced by reduced expression of osteogenic markers and diminished proliferation. Notably, HMGB2 overexpression reversed senescence‐mediated osteogenic impairment. In vivo studies of ovariectomy‐induced aging mice revealed a strong correlation between HMGB2 downregulation and osteoporosis progression, confirmed via immunohistochemistry. Mechanistically, HMGB2 promotes osteogenesis by directly suppressing TNF‐α and stabilizing the long non‐coding RNA TUG1, which subsequently inhibits pro‐inflammatory cytokines IL‐1β and IL‐6. This dual regulatory pathway highlights HMGB2's role in counteracting senescence‐driven osteogenic decline. Our study not only elucidates a novel HMGB2/TUG1 axis governing stem cell differentiation but also identifies HMGB2 as a promising therapeutic target for combating osteoporosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Provincial Key Laboratory of Animal Cells and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China.
- School of Mechanical Engineering, Shandong University, Jinan, China.
- Shandong Public Health Clinical Center, Shandong University, Jinan, China.
ORCID-Profile: Jing Zhao
Förderung
- | Natural Science Foundation of Shandong Province ()
- Natural Science Foundation of Shandong Province
Zitieren
APA
Li, Z., Cai, Y., Lu, Y., Qian, B., Yan, W., Gao, H., & Zhao, J. (2025). HMGB2 Deficiency in Bone Marrow Mesenchymal Stem Cells Promotes Age‐Related Osteoporosis by Inhibiting Osteoblast Differentiation via Inflammatory Factors. The FASEB Journal. https://doi.org/10.1096/fj.202500484rrrr
Vancouver
Li Z, Cai Y, Lu Y, Qian B, Yan W, Gao H, et al. HMGB2 Deficiency in Bone Marrow Mesenchymal Stem Cells Promotes Age‐Related Osteoporosis by Inhibiting Osteoblast Differentiation via Inflammatory Factors. The FASEB Journal. 2025. doi:10.1096/fj.202500484rrrr
BibTeX
@article{Li2025,
author = {Li, Zhiliang and Cai, Yuqing and Lu, Yao and Qian, Baoshuo and Yan, Wenxiu and Gao, Hongwei and Zhao, Jing},
title = {HMGB2 Deficiency in Bone Marrow Mesenchymal Stem Cells Promotes Age‐Related Osteoporosis by Inhibiting Osteoblast Differentiation via Inflammatory Factors},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500484rrrr}
}
EUVIMED